

AD _____

Award Number: W81XWH-06-1-0350

TITLE: The Role of Nuclear Receptor Coactivator A1B1 in Growth Factor-Mediated Mammary Tumorigenesis

PRINCIPAL INVESTIGATOR: Mark P Fereshteh (BS)

CONTRACTING ORGANIZATION: Georgetown University
Washington, DC 20057

REPORT DATE: March 2008

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-03-2008		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 15 Feb 07 – 14 Feb 08	
4. TITLE AND SUBTITLE The Role of Nuclear Receptor Coactivator A1B1 in Growth Factor-Mediated Mammary Tumorigenesis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0350	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Mark P Fereshteh (BS) E-Mail: mpf24@georgetown.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Washington, DC 20057				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: AIB1 (Amplified In Breast Cancer 1) is a nuclear receptor coactivator whose gene is amplified in 5-10% of breast cancers and both the mRNA and protein are overexpressed in ~30% of breast tumors. In vitro studies show that AIB1 plays a significant role in estrogen and IGF-1-induced cell proliferation. Germline knockout of the AIB1 gene leads to reduced somatic growth, abnormal reproductive function and reduced mammary gland development. Knockout of AIB1 expression also abrogates Ras-induced tumorigenesis. Furthermore, patients with tumors expressing high levels of the growth factor HER2/Neu in addition to AIB1 often develop anti-estrogen resistance to tamoxifen therapy. These findings imply that AIB1 plays a fundamental role in the development of hormone-independent breast cancer through growth factor mediated pathways. Nonetheless, the underlying mechanism of AIB1 regulation of growth factor mediated mammary neoplasia is unknown. In this investigation, I will utilize the MMTV-Neu mouse model (develop mammary gland tumors in 7-9 months) to elucidate the specific role of AIB1 in growth factor-induced mammary tumorigenesis.					
15. SUBJECT TERMS None provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	13	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	6
Key Research Accomplishments.....	11
Reportable Outcomes.....	11
Conclusion.....	11
References.....	12

INTRODUCTION

The nuclear receptor coactivator 3 (NCOA3; AIB1/SRC-3) is the only steroid receptor coactivator (SRC) family member that is amplified and overexpressed in several types of human epithelial tumors, such as breast and prostate cancer (1-3). The *AIB1/SRC-3* gene is amplified on chromosome 20q in 5-10% of human breast cancers, and is overexpressed at both mRNA and protein levels in ~30% of breast cancer cell lines and breast tumors (1, 2, 4). The overexpression of AIB1/SRC-3 or AIB1-Δ3 (a potent isoform of AIB1) (5) in transgenic mice increased mammary epithelial cell proliferation, insulin-like growth factor (IGF-1) signaling and initiated the development of mammary hyperplasia and tumorigenesis (6, 7). SRC-3 knockout (SRC-3^{-/-}) mice display decreased mammary gland (MG) development during pregnancy, abnormal reproductive function, and MG growth retardation (8, 9). The loss of SRC-3 in MMTV/v-Ha-ras mice suppresses MG ductal hyperplasia, MG tumorigenesis and IGF-1 signaling (8-10). We have shown that loss of AIB1/SRC-3 in MCF-7 breast cancer cells decreases IGF-1 signaling, IGF-1 receptor expression levels, and IGF-1-induced anchorage-independent growth (11). Consistent with a central role for AIB1/SRC-3 in growth factor signaling, we recently reported that AIB1/SRC-3 knockdown by siRNA decreases epidermal growth factor (EGFR/HER1) phosphorylation, and EGFR-dependent downstream mitogenic signaling (12). Taken together, the observations in animal and *in vitro* models indicate that AIB1/SRC-3 plays a significant role in several growth factor-induced pathways that are relevant to breast cancer cell survival and proliferation.

One of the most important oncogenes in human breast cancer is the HER2/*neu* growth factor receptor tyrosine kinase, which belongs to the epidermal growth factor receptor (EGFR/HER) family. HER2/*neu* positive breast cancer responds to the monoclonal antibody trastuzumab, however, patients frequently develop resistance to the therapy. HER2/*neu* is amplified and overexpressed in 30% of human breast cancers and its expression is correlated with negative

prognosis and shortened disease-free survival (13). It has been reported that the overexpression of *HER2/neu* is correlated with high *AIB1/SRC-3* mRNA levels in primary breast tumors (14). The overexpression of *AIB1/SRC-3* was also found to be correlated with increased *HER2/neu* expression and resistance to tamoxifen in ER-positive breast cancer patients (15-17). These findings suggest that the biological roles of *AIB1/SRC-3* and *HER2/neu* are linked in breast cancer and that *AIB1/SRC-3* may increase the sensitivity of breast cancer cells to *HER2/neu*-driven tumorigenesis.

To assess the importance of the interplay between *AIB1/SRC-3* and *Neu* in the development and progression of mammary cancer, I generated *MMTV-Neu/SRC-3^{+/-}*, and *MMTV-Neu/SRC-3^{-/-}* mice. The *MMTV-Neu* mouse model overexpresses wildtype *Neu* in the MGs, resulting in an activating transmembrane mutation in the *Neu* transgene that promotes mammary tumorigenesis (18, 19). This model is ideal for studying the role of *AIB1/SRC-3* in *Neu*-driven mammary tumorigenesis because it closely mimics the progression of human breast epithelial neoplasia, driven by the amplification and overexpression of the human homolog of *HER2/neu* (*ErbB2*) (13). Specifically, I want to determine whether the loss of *AIB1/SRC-3* in *MMTV-Neu* mice alters the mammary gland morphology in *MMTV-Neu* transgenic mice. I propose that the loss of *AIB1* will increase the latency and decrease the incidence of *HER2/Neu*-induced tumors.

BODY

Task 1 in my statement of work required the generation of female transgenic mice with the following genotypes: MMTV-*Neu*/SRC-3 wildtype (wt), MMTV-*Neu*/SRC-3 heterozygote (+/-), MMTV-*Neu*/SRC-3 knockout (-/-), as well as control litters MMTV-*Neu*, SRC-3^{wt}, SRC-3^{+/-} and SRC-3^{-/-} mice. In the previous report I discussed differences in primary and secondary branching of the mammary glands from the *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice. The overexpression of the *Neu* oncogene in mice is also associated with extensive lateral side budding, an abnormal mammary phenotype partly driven by increased growth factor signaling (20). Thus the preneoplastic MG ductal morphology in female *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice at 3-4 months of age was compared. Quantitative comparisons of the mammary gland whole mounts revealed a ~2 fold (p<0.001) and ~8 fold (p<0.001) decrease in lateral side budding in the *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice, respectively (Fig. 1A and 1C). Hematoxylin and eosin (H&E) stained sections also showed comparable differences in lateral side budding when SRC-3 levels were reduced in *Neu* mice (Fig. 1A lower panels).

Whole mount (WM) analysis at later stages of preneoplasia (6-7 months of age) revealed a considerable reduction (>60%, p<0.001) of lateral side budding in both the *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice relative to the *Neu*/SRC-3^{wt} mice (Fig. 1B and 1C). Consistent with previous reports using the SRC-3^{-/-} mouse model, *Neu*/SRC-3^{-/-} mice displayed decreased ductal branching (Fig. 1A and 1B, right panels), body weight and MG fat pad filling (data not shown) (8, 9). Interestingly, none of these effects was observed in the *Neu*/SRC-3^{+/-} mice. Of note is that the *Neu*/SRC3^{wt} and *Neu*/SRC3^{+/-} mice displayed no observable differences in ductal branching from 3-7 months of age.

Next, the relevance of SRC-3 in *Neu*-driven hyperplasia and tumor formation was investigated. Relative to the *Neu*/SRC-3^{+/-} mice, *Neu*/SRC-3^{wt} mice, 9-12 months of age, displayed more extensive lateral side budding and the formation of hyperplastic alveolar nodules (HANs) in

the MGs adjacent to the mammary tumors (Fig. 2A). The *Neu/SRC-3^{-/-}* mice displayed no discernible preneoplastic changes (Fig. 2A).

The appearance of palpable mammary tumors is shown in a Kaplan Meier plot of 25 *Neu/SRC-3^{wt}*, 23 *Neu/SRC-3^{+/-}* and 14 *Neu/SRC-3^{-/-}* mice (Fig. 2B). 77% of the *Neu/SRC-3^{wt}* mice developed mammary tumors from 7-15 months with a median age of 9 months. *Neu/SRC-3^{+/-}* mice displayed a significant delay in tumor onset, with 70% of the mice developing mammary tumors from 15-24 months with a median age of 16 months. 100% of the *Neu/SRC-3^{-/-}* mice observed up to 24 months of age were protected from mammary tumor formation (Fig. 2B). Despite the delayed tumorigenesis in the *Neu/SRC-3^{+/-}* mice there was no difference in the multiplicity of tumors per mouse (Fig 2B lower panel). It was also noted that *Neu/SRC-3^{+/-}* tumors had large areas of necrotic tissue in all of the tumors examined (n=3 mice) (Fig. 2C). In contrast, all of the tumors from the *Neu/SRC-3^{wt}* mice displayed a noticeable increase in blood vessels when compared to the tumors from the *Neu/SRC-3^{+/-}* mice (n=8 mice) (Fig. 2C). Relative to the *Neu/SRC-3^{wt}* mice, a ~20% (p<0.05) reduction was observed in the average number of blood vessels per field in the *Neu/SRC-3^{+/-}* mice (Fig. 2C, bottom panel).

Currently, I am in the process of investigating changes in cell proliferation, cell cycle regulators (cyclin D1 and cyclin E) as well as how the reduction of SRC-3 mediates Neu receptor activation and Neu-induced downstream kinase signaling pathways (ie; MAPK, JNK and AKT). The mediation of signaling and proliferation will be investigated using immunohistochemical and western blot assays for the proteins of interest at both the pre-invasive (3-7 months) and neoplastic time points.

Figure 1. Decreased mammary gland lateral side budding in female MMTV-*Neu* mice with reduced levels of SRC-3 (A and B) Representative MG whole mount (WM, magnification: 4x) (top panels) and hematoxylin and eosin (H&E, magnification: 20x) (bottom panels) stained tissue sections from mice at (A) 3-4 and (B) 6-7 months of age. The data are representative of MGs taken from four mice from each genotype. Black arrows indicate lateral side budding in WM and H&E stained sections. (C) Quantification of lateral side budding along the MG ducts. The number of lateral side buds were counted from 10 fields per WM from each mouse (magnification: 10x). Data are expressed as the mean $\pm$ SD (n=4 mice from each genotype). *, $p < 0.05$ and **, $p < 0.001$, one-way ANOVA.





Figure 2. Reduced SRC-3 levels in MMTV-*Neu* mice increases the latency of *Neu*-driven mammary tumorigenesis (A) Representative MG whole mounts (WM, magnification: 10x) (top panels) and hematoxylin and eosin (H&E, magnification: 20x) (lower panels) stained tissue sections from MGs adjacent to tumors from *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-}, and *Neu*/SRC-3^{-/-} mice. The data is representative of four mice examined from each genotype. Black arrows represent lateral side budding and the white arrow (top panel) indicates the presence of a typical hyperplastic alveolar nodule. (B, upper panel) Kaplan-Meier analysis of tumor-free incidence comparing *Neu*/SRC-3^{wt} with the *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice. (B, lower panel) Quantification of the number of tumors per mouse from the *Neu*/SRC-3^{wt} (n=8) and *Neu*/SRC-3^{+/-} mice (n=13) was analyzed using the chi-squared test. (C) Photographs showing representative primary mammary tumors harvested from *Neu*/SRC-3^{wt} (9 months of age) and *Neu*/SRC-3^{+/-} (19 months of age) mice (top panels). Representative paraffin-embedded H&E stained mammary tumors from *Neu*/SRC-3^{wt} and *Neu*/SRC-3^{+/-} mice. Representative blood vessels (BV) (left panels) and areas of necrosis (N) (right panels). The bar chart represents the quantification of the average number of blood vessels per field in tumors from the *Neu*/SRC-3^{wt} (n=8) and *Neu*/SRC-3^{+/-} (n=3) mice. 10 fields were counted per mouse (magnification: 40x). Data are expressed as mean $\pm$ SD. *, p<0.05, Student's t-test.



KEY RESEARCH ACCOMPLISHMENTS

- Pathological analysis of wholemounts of the *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice at 3-4, 6-7 months of age.
- Histological analysis of H&E stains of the *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice at 3-4, 6-7 months of age.
- Pathological analysis of tumors from the *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-}.
- Histological analysis of H&E stains of the tumors from *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-}.
- Quantification of tumor-free incidence in *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice

REPORTABLE OUTCOMES

This work has been presented and won the finalist award at Georgetown University's student research days poster competition.

CONCLUSIONS

In conclusion, this study demonstrates that SRC-3 plays a major role in *Neu*-induced preneoplastic phenotypic changes and tumorigenesis in the mammary gland of mice. Only a 50% reduction in SRC-3 levels in the mammary epithelium can delay HER2/*Neu*-driven tumorigenesis and reduce the total number of tumors that develop. In addition, the reduction in SRC-3 may reduce the angiogenesis in the tumors. Our results emphasize that targeting endogenous SRC-3 could provide greater efficacy to the current therapies used to treat tumors overexpressing HER2/*Neu*. I am currently collecting data to address which signaling cascades are mediating the phenotype observed in the *Neu*/SRC-3^{wt}, *Neu*/SRC-3^{+/-} and *Neu*/SRC-3^{-/-} mice.

ABBREVIATIONS

AIB1- Amplified in breast cancer 1
EGF- Epidermal growth factor
ER- Estrogen receptor
GR- Glucocorticoid receptor
GRIP1- Glucocorticoid receptor interacting protein 1
H&E- Hematoxyllin and eosin
IGF- Insulin-like growth factor
IHC- Immunohistochemistry
MG- Mammary gland
MMTV- Mouse mammary tumor virus
PCNA- Proliferating cell nuclear antigen
PCR- Polymerase chain reaction
PPAR- Peroxisome proliferator-activated receptor
RAR- Retinoic acid receptor
rtTA- Reverse tetracycline transactivator
SRC- Steroid receptor coactivator

REFERENCES

1. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M., and Meltzer, P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science*, 277: 965-968, 1997.
2. List, H. J., Reiter, R., Singh, B., Wellstein, A., and Riegel, A. T. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. *Breast Cancer Res Treat*, 68: 21-28, 2001.
3. Gnanapragasam, V. J., Leung, H. Y., Pulimood, A. S., Neal, D. E., and Robson, C. N. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. *Br J Cancer*, 85: 1928-1936, 2001.
4. Bautista, S., Valles, H., Walker, R. L., Anzick, S., Zeillinger, R., Meltzer, P., and Theillet, C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. *Clin Cancer Res*, 4: 2925-2929, 1998.
5. Reiter, R., Wellstein, A., and Riegel, A. T. An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. *J Biol Chem*, 276: 39736-39741, 2001.
6. Tilli, M. T., Reiter, R., Oh, A. S., Henke, R. T., McDonnell, K., Gallicano, G. I., Furth, P. A., and Riegel, A. T. Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. *Mol Endocrinol*, 19: 644-656, 2005.
7. Torres-Arzayus, M. I., Font de Mora, J., Yuan, J., Vazquez, F., Bronson, R., Rue, M., Sellers, W. R., and Brown, M. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. *Cancer Cell*, 6: 263-274, 2004.
8. Wang, Z., Rose, D. W., Hermanson, O., Liu, F., Herman, T., Wu, W., Szeto, D., Gleiberman, A., Krones, A., Pratt, K., Rosenfeld, R., Glass, C. K., and Rosenfeld, M. G. Regulation of somatic growth by the p160 coactivator p/CIP. *Proc Natl Acad Sci U S A*, 97: 13549-13554, 2000.
9. Xu, J., Liao, L., Ning, G., Yoshida-Komiya, H., Deng, C., and O'Malley, B. W. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal

- growth, puberty, female reproductive function, and mammary gland development. *Proc Natl Acad Sci U S A*, 97: 6379-6384, 2000.
10. Kuang, S. Q., Liao, L., Zhang, H., Lee, A. V., O'Malley, B. W., and Xu, J. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. *Cancer Res*, 64: 1875-1885, 2004.
 11. Oh, A., List, H. J., Reiter, R., Mani, A., Zhang, Y., Gehan, E., Wellstein, A., and Riegel, A. T. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. *Cancer Res*, 64: 8299-8308, 2004.
 12. Lahusen, T., Fereshteh, M., Oh, A., Wellstein, A., and Riegel, A. T. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. *Cancer Res*, 67: 7256-7265, 2007.
 13. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*, 235: 177-182, 1987.
 14. Bouras, T., Southey, M. C., and Venter, D. J. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. *Cancer Res*, 61: 903-907, 2001.
 15. Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A., Wong, J., Allred, D. C., Clark, G. M., and Schiff, R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. *J Natl Cancer Inst*, 95: 353-361, 2003.
 16. Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., and Schiff, R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. *J Natl Cancer Inst*, 96: 926-935, 2004.
 17. Kirkegaard, T., McGlynn, L. M., Campbell, F. M., Muller, S., Tovey, S. M., Dunne, B., Nielsen, K. V., Cooke, T. G., and Bartlett, J. M. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. *Clin Cancer Res*, 13: 1405-1411, 2007.
 18. Siegel, P. M., Dankort, D. L., Hardy, W. R., and Muller, W. J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. *Mol Cell Biol*, 14: 7068-7077, 1994.
 19. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proc Natl Acad Sci U S A*, 89: 10578-10582, 1992.
 20. Andrechek, E. R., Hardy, W. R., Siegel, P. M., Rudnicki, M. A., Cardiff, R. D., and Muller, W. J. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. *Proc Natl Acad Sci U S A*, 97: 3444-3449, 2000.